Central vision can fade slowly with age-related macular degeneration. Faces blur. Words smear on a page. A dark spot can sit ...

NEW YORK CITY -- A form of light therapy led to durable improvement in visual acuity for patients with dry age-related macular degeneration, according to interim results from an ongoing randomized ...

CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...

The PRIMA system is a subretinal implant designed to restore central vision in GA patients by replacing failed photoreceptors ...

Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Lumevoq demonstrated continued vision improvement in ...

SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, ...

Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...